Urate in Parkinson's Disease: More Than a Biomarker?

被引:79
作者
Chen, Xiqun [1 ]
Wu, Guanhui [1 ,2 ]
Schwarzschild, Michael A. [1 ]
机构
[1] Harvard Univ, Massachusetts Gen Hosp, Dept Neurol, Sch Med, Charlestown, MA 02129 USA
[2] Suzhou Municipal Hosp, Suzhou, Peoples R China
基金
美国国家卫生研究院;
关键词
Urate; Parkinson's disease; Oxidative stress; Clinical trial; Antioxidant; Neuroprotectant; Neurodegeneration; Neuroprotection; Biomarker; Disease modifier; Neurodegenerative diseases; Purine; Risk factor; URIC-ACID LEVELS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MILD COGNITIVE IMPAIRMENT; ISCHEMIC BRAIN-INJURY; SUBSTANTIA-NIGRA; OXIDATIVE STRESS; PLASMA URATE; IN-VIVO; DOPAMINERGIC-NEURONS; ANTIOXIDANT CAPACITY;
D O I
10.1007/s11910-012-0282-7
中图分类号
R74 [神经病学与精神病学];
学科分类号
100204 [神经病学];
摘要
Parkinson's disease (PD) is a progressive neurodegenerative disease with characteristic motor manifestations. Although appreciation of PD as a multisystem disorder has grown, loss of dopaminergic neurons in the substantia nigra remains a pathological and neurochemical hallmark, accounting for the substantial symptomatic benefits of dopamine replacement therapies. However, currently no treatment has been shown to prevent or forestall the progression of the disease in spite of tremendous efforts. Among multiple environmental and genetic factors that have been implicated in the pathogenesis of PD, oxidative stress is proposed to play a critical role. A recent confluence of clinical, epidemiological, and laboratory evidence identified urate, an antioxidant and end product of purine metabolism, as not only a molecular predictor for both reduced risk and favorable progression of PD but also a potential neuroprotectant for the treatment of PD. This review summarizes recent findings on urate in PD and their clinical implications.
引用
收藏
页码:367 / 375
页数:9
相关论文
共 99 条
[1]
6-HYDROXYDOPAMINE, A NEW OXIDATION MECHANISM [J].
ADAMS, RN ;
BLANK, L ;
KAROLCZAK, M ;
MURRILL, E ;
MCCREERY, R .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1972, 17 (02) :287-+
[2]
Rasagiline, Parkinson neuroprotection, and delayed-start trials Still no satisfaction? [J].
Ahlskog, J. Eric ;
Uitti, Ryan J. .
NEUROLOGY, 2010, 74 (14) :1143-1148
[3]
Oxidative DNA damage in the parkinsonian brain: An apparent selective increase in 8-hydroxyguanine levels in substantia nigra [J].
Alam, ZI ;
Jenner, A ;
Daniel, SE ;
Lees, AJ ;
Cairns, N ;
Marsden, CD ;
Jenner, P ;
Halliwell, B .
JOURNAL OF NEUROCHEMISTRY, 1997, 69 (03) :1196-1203
[4]
Gout and risk of Parkinson disease -: A prospective study [J].
Alonso, Alvaro ;
Garcia Rodriguez, Luis A. ;
Logroscino, Giancarlo ;
Hernan, Miguel A. .
NEUROLOGY, 2007, 69 (17) :1696-1700
[5]
Uric acid and evolution [J].
Alvarez-Lario, Bonifacio ;
Macarron-Vicente, Jesus .
RHEUMATOLOGY, 2010, 49 (11) :2010-2015
[6]
Translational Stroke Research of the Combination of Thrombolysis and Antioxidant Therapy [J].
Amaro, Sergio ;
Chamorro, Angel .
STROKE, 2011, 42 (05) :1495-1499
[7]
URIC-ACID PROVIDES AN ANTIOXIDANT DEFENSE IN HUMANS AGAINST OXIDANT-CAUSED AND RADICAL-CAUSED AGING AND CANCER - A HYPOTHESIS [J].
AMES, BN ;
CATHCART, R ;
SCHWIERS, E ;
HOCHSTEIN, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1981, 78 (11) :6858-6862
[8]
Serum uric acid levels in patients with Parkinson's disease: Their relationship to treatment and disease duration [J].
Andreadou, Elisabeth ;
Nikolaou, Chryssoula ;
Gournaras, Filippos ;
Rentzos, Michael ;
Boufidou, Fotini ;
Tsoutsou, Anthoussa ;
Zournas, Christos ;
Zissimopoulos, Vassilis ;
Vassilopoulos, Demetrios .
CLINICAL NEUROLOGY AND NEUROSURGERY, 2009, 111 (09) :724-728
[9]
Uric acid associates with cognition in Parkinson's disease [J].
Annanmaki, Tua ;
Pessala-Driver, Anniina ;
Hokkanen, Laura ;
Murros, Kari .
PARKINSONISM & RELATED DISORDERS, 2008, 14 (07) :576-578
[10]
Low plasma uric acid level in Parkinson's disease [J].
Annanmaki, Tua ;
Muuronen, Antti ;
Murros, Kari .
MOVEMENT DISORDERS, 2007, 22 (08) :1133-1137